EP0627934A4 - Early antigen for autoimmune diabetes. - Google Patents

Early antigen for autoimmune diabetes.

Info

Publication number
EP0627934A4
EP0627934A4 EP93907049A EP93907049A EP0627934A4 EP 0627934 A4 EP0627934 A4 EP 0627934A4 EP 93907049 A EP93907049 A EP 93907049A EP 93907049 A EP93907049 A EP 93907049A EP 0627934 A4 EP0627934 A4 EP 0627934A4
Authority
EP
European Patent Office
Prior art keywords
autoimmune diabetes
early antigen
antigen
early
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93907049A
Other languages
German (de)
French (fr)
Other versions
EP0627934A1 (en
Inventor
C Garrison Fathman
Lisa Paborsky
Cohava Gelber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Leland Stanford Junior University
Original Assignee
Immulogic Pharmaceutical Corp
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp, Leland Stanford Junior University filed Critical Immulogic Pharmaceutical Corp
Publication of EP0627934A1 publication Critical patent/EP0627934A1/en
Publication of EP0627934A4 publication Critical patent/EP0627934A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP93907049A 1992-02-27 1993-02-25 Early antigen for autoimmune diabetes. Withdrawn EP0627934A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84287492A 1992-02-27 1992-02-27
US842874 1992-02-27
PCT/US1993/001716 WO1993016725A1 (en) 1992-02-27 1993-02-25 Early antigen for autoimmune diabetes

Publications (2)

Publication Number Publication Date
EP0627934A1 EP0627934A1 (en) 1994-12-14
EP0627934A4 true EP0627934A4 (en) 1997-01-08

Family

ID=25288461

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93907049A Withdrawn EP0627934A4 (en) 1992-02-27 1993-02-25 Early antigen for autoimmune diabetes.

Country Status (5)

Country Link
EP (1) EP0627934A4 (en)
JP (1) JPH07508503A (en)
AU (1) AU3778993A (en)
CA (1) CA2130997A1 (en)
WO (1) WO1993016725A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2842570B1 (en) * 2007-03-07 2020-05-06 UTI Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007117A1 (en) * 1988-12-13 1990-06-28 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NO306996B1 (en) * 1989-02-17 2000-01-24 Bayer Ag Isolated pancreatic cell (ICA) antigen for in vitro use
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007117A1 (en) * 1988-12-13 1990-06-28 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9316725A1 *

Also Published As

Publication number Publication date
WO1993016725A1 (en) 1993-09-02
AU3778993A (en) 1993-09-13
CA2130997A1 (en) 1993-09-02
EP0627934A1 (en) 1994-12-14
JPH07508503A (en) 1995-09-21

Similar Documents

Publication Publication Date Title
EP0627932A4 (en) Novel antibody construct.
EP0634319A3 (en) Crank device.
OA09266A (en) Containers.
EP0621721A3 (en) Document surrogates.
EP0676966A4 (en) Antibodies directed against binding-associated epitopes.
EP0578819A4 (en) Icam-related protein.
EP0640758A3 (en) Charge forming device.
GB9412166D0 (en) Retargetting antibodies
DE69105726D1 (en) Pipette.
EP0613064A3 (en) Developer device.
ZA939574B (en) Shaped charges.
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
DE58904130D1 (en) Elektrophotographischer toner.
EP0640398A3 (en) Centrifuge.
EP0627934A4 (en) Early antigen for autoimmune diabetes.
EP0668918A4 (en) Disease associated human autoantibodies specific for human thyroid peroxidase.
DE58903960D1 (en) Elektrophotographische toner.
EP0629922A3 (en) Charging device.
ZA89258B (en) Monoclonal antibodies
EP0629857A3 (en) Immunoassay for quantitatively determining antigens.
GB8820036D0 (en) Monoclonal antibodies
EP0654532A4 (en) Antimucoglycoprotein monoclonal antibody.
EP0497764A4 (en) Immunoassay for pyridostigmine.
EP0612545A3 (en) Fixing device for skibinding.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19961122

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940928